Conjugated Linoleic Acid Increased C-reactive Protein In Human Subjects

この研究の注釈:

4.2g of CLA daily for 3 months was able to raise C-Reactive Protein levels without influencing TNF-a levels or cellular adhesion factors.


Conjugated Linoleic Acid Modulates Immune Responses In Patients With Mild To Moderately Active Crohn’s Disease

この研究の注釈:

6g of supplementation (77% CLA by weight; 1:1 ratio of the two main isomers) for 12 weeks noted significant improvements in quality of life () associated with supplementation (pilot study, no placebo group). The benefit seen according to CDAI rating was 13.1% at week 6 and 23.6% at 12 weeks with the authors suggesting that it may not be clinically significant.

Secretion of IL-2 increased from isolated CD4+ and CD8+ lymphocytes, while serum IL-6 was higher after 12 weeks. IL-8, IL-1β, IL-10, TNF-α, or IL-12p70 were all unaffected, and lymphocyte secretion of TNF-α and IFNy was reduced.


Milk Enriched With Conjugated Linoleic Acid Fails To Alter Blood Lipids Or Body Composition In Moderately Overweight, Borderline Hyperlipidemic Individuals

この研究の注釈:

Three groups were done in overweight and unhealthy adults; milk with naturally occurring c9t11 CLA, milk with the same (1.3g/day) content of mixed isomer CLA, and milk with 0.2g CLA (CLA depleted). Each trial period was 8 weeks, with a 4 week washout, and each subject was randomized to each trial period.

No difference was noted in triglycerides or cholesterol levels between treatment periods, nor were liver enzymes altered.


Conjugated Linoleic Acid Supplementation For 8 Weeks Does Not Affect Body Composition, Lipid Profile, Or Safety Biomarkers In Overweight, Hyperlipidemic Men

この研究の注釈:

Relative to safflower oil as a control at 3.5g daily, two experimental groups were used. 3.5g of oil comprising 2.7g of 50/50 CLA isomers, and 3.5g oil comprising 2.7g of jsut the c9t11 isomer. Population was overweight and hyperlipidemic men, and no dietary controls were in place (free-living conditions) over 56 days.

No differences existed in lean mass, fat mass, or weight; nor were any trends noted. A decrease in circulating TNF-a was noted with both CLA treatments, and all other parameters came back statistically insignificant.